Oral rat LD50: > 16 gm/kg. Investigated as a tumorigen, mutagen, reproductive effector. Symptoms of overdose include agitation, confusion, diarrhea, fever, overactive reflexes, poor coordination, restlessness, shivering, sweating, talking or acting with excitement you cannot control, trembling or shaking, twitching, and vomiting.
An essential amino acid that is necessary for normal growth in infants and for nitrogen balance in adults. It is a precursor of indole alkaloids in plants. It is a precursor of serotonin (hence its use as an antidepressant and sleep aid). It can be a precursor to niacin, albeit inefficiently, in mammals.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tryptophan. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Tryptophan. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Tryptophan. |
| Hydrocodone | Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tryptophan. |
| Methotrimeprazine | Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Tryptophan may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tryptophan. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Tryptophan. |
| Orphenadrine | Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Tryptophan. |
| Pramipexole | Tryptophan may increase the sedative activities of Pramipexole. |
| Ropinirole | Tryptophan may increase the sedative activities of Ropinirole. |
| Rotigotine | Tryptophan may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Tryptophan. |
| Sodium oxybate | Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Tryptophan. |
| Thalidomide | Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Tryptophan. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Tryptophan. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Tryptophan is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Tryptophan is combined with Phenindione. |
| Warfarin | The risk or severity of adverse effects can be increased when Tryptophan is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Tryptophan is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when Tryptophan is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Tryptophan is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when Tryptophan is combined with Coumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when Tryptophan is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Tryptophan is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Tryptophan is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Tryptophan is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Tryptophan is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Tryptophan is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Tryptophan is combined with (S)-Warfarin. |
| Mirtazapine | Tryptophan may increase the serotonergic activities of Mirtazapine. |
| Furazolidone | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Furazolidone. |
| Procaine | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Procaine. |
| Procarbazine | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Procarbazine. |
| Rasagiline | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Rasagiline. |
| Pargyline | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Pargyline. |
| Safinamide | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Safinamide. |
| 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline. |
| Hydracarbazine | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Hydracarbazine. |
| Benmoxin | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Benmoxin. |
| Mebanazine | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Mebanazine. |
| Octamoxin | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Octamoxin. |
| Pheniprazine | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Pheniprazine. |
| Phenoxypropazine | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Phenoxypropazine. |
| Pivhydrazine | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Pivhydrazine. |
| Safrazine | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Safrazine. |
| Caroxazone | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Caroxazone. |
| Harmaline | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Harmaline. |
| Brofaromine | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Brofaromine. |
| Tranylcypromine | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Tranylcypromine. |
| Phenelzine | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Phenelzine. |
| Minaprine | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Minaprine. |
| Selegiline | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Selegiline. |
| Moclobemide | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Moclobemide. |
| Isocarboxazid | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Isocarboxazid. |
| Clorgiline | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Clorgiline. |
| Iproniazid | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Iproniazid. |
| Nialamide | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Nialamide. |
| Pirlindole | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Pirlindole. |
| Toloxatone | The risk or severity of serotonin syndrome and hypomania can be increased when Tryptophan is combined with Toloxatone. |
| Ethanol | Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Tryptophan. |
| Zimelidine | The risk or severity of adverse effects can be increased when Tryptophan is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Tryptophan is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Tryptophan is combined with Seproxetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Tryptophan is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Tryptophan is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Tryptophan is combined with Duloxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Tryptophan is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Tryptophan is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Tryptophan is combined with Nefazodone. |
| Milnacipran | The risk or severity of adverse effects can be increased when Tryptophan is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Tryptophan. |
| Levomilnacipran | The risk or severity of serotonin syndrome can be increased when Tryptophan is combined with Levomilnacipran. |
| Indalpine | The risk or severity of adverse effects can be increased when Tryptophan is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Tryptophan is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Tryptophan is combined with Alaproclate. |
| Methylene blue | Tryptophan may increase the serotonergic activities of Methylene blue. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Tryptophan is combined with Cyproheptadine. |
| Propiomazine | The risk or severity of CNS depression can be increased when Tryptophan is combined with Propiomazine. |
| Zopiclone | The risk or severity of adverse effects can be increased when Tryptophan is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Tryptophan. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Tryptophan. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Tryptophan. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Tryptophan is combined with Ethchlorvynol. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Tryptophan is combined with Succinylcholine. |
| Eletriptan | The risk or severity of CNS depression can be increased when Tryptophan is combined with Eletriptan. |
| Enflurane | The risk or severity of CNS depression can be increased when Tryptophan is combined with Enflurane. |
| Butabarbital | The risk or severity of CNS depression can be increased when Tryptophan is combined with Butabarbital. |
| Butalbital | The risk or severity of CNS depression can be increased when Tryptophan is combined with Butalbital. |
| Methysergide | The risk or severity of CNS depression can be increased when Tryptophan is combined with Methysergide. |